tirzepatide uptodate for diabetes: on track to SURPASS current therapy FDA Grants Tirzepatide a New

When paired with personalized lifestyle support, they encourage long-lasting results, making it easier to stay at a healthy weight and prevent future setbacks

The samples were centrifuged by 5 min, at 4 C, using a speed 12 000 rpm

Fatigue, depression, and sleep disorders are more prevalent in patients with metabolic-associated fatty liver diseases

B12 monitoring becomes more important the longer you use semaglutide

Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management (Mounjaro) and chronic weight management (Zepbound) in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity